

10-4-2019

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML).

Lindsay Wilde

Jillian Cooper

Zi-Xuan Wang

Jinglan Liu

Follow this and additional works at: <https://jdc.jefferson.edu/medoncfp>Part of the [Oncology Commons](#)

[Let us know how access to this document benefits you](#)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.



Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)

Lindsay Wilde^{1*}, Jillian Cooper², Zi-Xuan Wang^{3,4} and Jinglan Liu⁵

¹ Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States, ² Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States, ³ Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, United States, ⁴ Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, United States, ⁵ Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, United States

t(8;21)(q22;q22) is present in ~5–10% of patients with *de novo* acute myeloid leukemia (AML) and is associated with a better overall prognosis. Variants of the t(8;21) have been described in the literature, however, their clinical and prognostic significance has not been well-characterized. Molecular profiling of these cases has not previously been reported but may be useful in better defining the prognosis of this subset of patients. We present two cases of variant t(8;21) AML including clinical, cytogenetic, and molecular data.

Keywords: acute myeloid leukemia, t(8;21), cytogenetics, core binding factor, variant

OPEN ACCESS

Edited by:

Pierluigi Porcu,
Sidney Kimmel Cancer Center,
United States

Reviewed by:

Alejandro Majlis,
Las Condes Clinic, Chile
Sarah Wall,
The Ohio State University,
United States

*Correspondence:

Lindsay Wilde
lindsay.wilde@jefferson.edu

Specialty section:

This article was submitted to
Hematologic Malignancies,
a section of the journal
Frontiers in Oncology

Received: 17 May 2019

Accepted: 20 September 2019

Published: 04 October 2019

Citation:

Wilde L, Cooper J, Wang Z-X and
Liu J (2019) Clinical, Cytogenetic, and
Molecular Findings in Two Cases of
Variant t(8;21) Acute Myeloid
Leukemia (AML).
Front. Oncol. 9:1016.
doi: 10.3389/fonc.2019.01016

BACKGROUND

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) is known as a core binding factor AML. Along with inv(16)(p13;q22)/t(16;16)(p13;q22), this cytogenetic abnormality has been shown to have a more favorable prognosis, especially when treated with high dose cytarabine based therapy (1–3). The t(8;21) is found in ~5–10% of *de novo* AML and results in the creation of the fusion gene RUNX1-RUNX1T1 (1, 4–6). In most affected individuals, the chromosomal breakpoints are located at intron 5 of the RUNX1 gene and intron 1 of the RUNX1T1 resulting in an in-frame fusion of the N-terminal 177 amino acids of RUNX1 with almost the entire RUNX1T1 protein (7). The RUNT domain from RUNX1, the four nery homology regions (NHR), and a nuclear localization signal (NLS) from RUNX1T1 are major functional domains of the fusion protein (8, 9). By direct or indirect binding to target DNA regions, the RUNX1-RUNX1T1 regulates the expression of various groups of genes involved in multiple signaling pathways. It has been shown that the RUNX1-RUNX1T1 alone is not sufficient for leukemogenic transformation, and the number of mutations necessary for the development of AML1-ETO leukemia is still unknown (5, 6, 10). Variant translocations account for ~3–4% of leukemias with RUNX1/RUNX1T1 fusion transcripts, some of which are cytogenetically cryptic and can only be identified by molecular approaches (e.g., quantitative PCR). Clinical consequences of these variants are poorly defined (11–15). Here, we present two similar cases of variant t(8;21) identified at our institution, their molecular findings on next generation sequencing, and their clinical outcomes.

MATERIALS AND METHODS

Conventional Cytogenetic Analysis

The bone marrow specimens were cultured in MarrowMAX medium (Invitrogen, Carlsbad, CA) for 24 and 48 h, respectively. Metaphase chromosomes for Giemsa *banding* pattern by trypsin

digestion with Wright stain (*GTW banding*) were prepared according to standard procedures. Twenty metaphases were karyotyped with GenASIs BandView Analysis System (Applied Spectral Imaging, Carlsbad, CA), and karyograms were described according to the International System for Human Cytogenetic Nomenclature 2016.

Fluorescent *in-situ* Hybridization (FISH) Assay

FISH analysis on monolayer interphase nuclei and metaphases harvested from bone marrow cultures was undertaken using commercially available FISH probes in the AML panel (Vysis, Abbott Park, IL). Standard FISH hybridization and washing protocols were followed. The slides were then counterstained with the 4',6-diamidino-2-phenylindole (DAPI). Hybridization signals were captured and analyzed with a GenASIs FISHView Analysis System (Applied Spectral Imaging, Carlsbad, CA). At least 200 cells were scored for each probe set.

Molecular Pathology Studies

Hematological Malignancy Gene Panel Mutation Analysis, a comprehensive targeted next generation sequencing (NGS) assay, FLT3 internal tandem duplication (ITD) mutation analysis, and JAK2 V617F Mutation Analysis were performed in the Molecular and Genomic Pathology Laboratory of Thomas Jefferson University Hospital. In brief, the NGS panel was designed in-house to detect somatic mutations in 48 genes that are recurrently mutated in myeloid malignancies. Input DNA is processed using the Illumina TruSight(TM) Myeloid Sequencing Panel and sequenced on an Illumina MiSeq sequencer. The assay has sufficient sensitivity to detect mutations present in a heterozygous state at a 5% allele frequency. FLT3 internal tandem duplication (ITD) mutation analysis was performed by amplifying a 329 base-pair fragment of the FLT3 gene including the ITD insertion sites and is sufficient to detect an ITD of 1% allele frequency. The JAK2 V617F mutation analysis was performed using an allelic discrimination assay according to the manufacturer's instruction (MutaScreen Assay, Ipsogen).

CASES

Patient #1

Clinicopathologic Findings

A 62-year-old female with a history of hypertension and adenocarcinoma of the breast treated with radiation and tamoxifen was referred to our hospital for an abnormal complete blood count (CBC). On admission, her white blood cell (WBC) count was $5 \times 10^3/\mu\text{L}$ with 17% blasts, hemoglobin was 9.1 g/dL, and platelet count was $22 \times 10^3/\mu\text{L}$. Bone marrow biopsy revealed a prominent population of blasts with round to irregular, intermediate sized nuclei, prominent nucleoli, and scant to moderate cytoplasm, comprising 59% by manual count. Several blasts contained dark azurophilic and large salmon colored cytoplasmic granules. Auer rods were not apparent. Concomitant flow cytometry of the bone marrow detected an increased myeloblast population showing the following antigenic profile: CD10-, CD13-, CD14-, CD16-,

TABLE 1 | Clinicopathologic findings in two patients with variant t(8;21).

Characteristics	Patient #1	Patient #2
Age/Sex	62/F	63/F
Diagnosis	Acute myeloid leukemia	Acute myeloid leukemia
Hemoglobin	9.1 g/dL	9.1 g/dL
Platelet	22,000 B/L	4,000 B/L
WBC	5.0 B/L	6.1 B/L
PB blasts, %	17	67
BM blasts,%	59	75
Cellularity,%	50	60
Morphology	Blasts with round to irregular, intermediate sized nuclei, prominent nucleoli, and scant to moderate cytoplasm; no Auer rods	Medium sized blasts with fine nuclear chromatin, small nucleoli, and scant cytoplasm; no cytoplasmic granules or Auer rods
Immunophenotype	CD10-, CD13-, CD14-, CD16-, CD19+ (aberrant), CD33+(dim), CD34+(bright), CD38+, CD56-, CD64-, CD117+, HLA-DR+(bright), MPO+	CD4+ (dim, partial), CD13- (partial, dim), CD14-, CD33+, CD34+, CD38+ (partial, dim), CD56, CD61 (dim), CD64-, CD117+, and HLA DR+ (dim).

CD19+ (aberrant), CD33+(dim), CD34+(bright), CD38+, CD56-, CD64-, CD117+, HLA-DR+(bright) (Table 1). This was consistent with a diagnosis of AML.

Conventional Cytogenetics and FISH

Conventional cytogenetics study revealed an apparently reciprocal translocation between the long arms of chromosomes 8 and 21 at 8q22 and 21q22 [t(8;21)] in twenty of twenty metaphases analyzed. However, FISH on interphase nuclei showed an atypical pattern with one fusion signal representing either der(8) or der(21) (indistinguishable on interphase nuclei) resulting from a typical translocation, two green signals (2G) representing either an intact or partial RUNX1 (AML1) gene at 21q22, and a single red signal (1R) representing either an intact or partial RUNX1T1 (ETO) gene at 8q22. FISH on metaphases showed a derivative chromosome 8 carrying a fusion signal of RUNX1T1 and RUNX1, a derivative chromosome 21 carrying the green colored RUNX1 (AML1) signal alone consistent with an absence of the RUNX1T1 (ETO) signal and indicative of a sub-microscopic deletion following the t(8;21) (the green signal in fact represented the 3' RUNX1 gene), a copy of a normal chromosome 8 (red), and a copy of a normal chromosome 21 (green) (Figure 1). The final cytogenetic diagnosis for this patient was:

46,XX,der(8)t(8;21)(q22;q22),der(21)del(8)(q22q22)t(8;21)(20). ish der(8)t(8;21)(q22;q22)(3'RUNX1T1+,5'RUNX1+),der(21)del(8)(q22q22)t(8;21)(3'RUNX1+)(3).nuc ish(RUNX1T1x2, RUNX1x3)(RUNX1 con RUNX1T1x1)[165/200], (RPN1, MECOM,EGR1,DEK,D7S522,ASS1,ABL1,CAN,KMT2A,PML, CBFβ,RARA,TP53,BCR)x2[200].




TABLE 2 | Hematologic malignancy gene panel findings in two patients with variant t(8;21).

Gene	Patient #1			Patient #2
	ASXL1	DNMT3A	IDH1	RAD21
Genomic position (hg19)	chr20:31023092	chr2:25469128	chr2:209113113	chr8:117866547
Nucleotide change	c.2578delA (NM_015338.5)	c.1328_1329dupCT (NM_175629.2)	c.394C>T (NM_005896.2)	c.1097delC (NM_006265.2)
Amino acid change	p.R860Efs*7	p.E444Lfs*208	p.R132C	p.T366Kfs*4
Cosmic ID	None	4678897:4678898	COSM28747	None
Altered allele frequency	44.80%	43.60%	41.30%	41.20%
Classification	Pathogenic	Pathogenic	Pathogenic	Pathogenic

Molecular Pathology Assays

A pathogenic mutation in the gene RAD21 was identified (Table 2) and the study of internal tandem duplications (ITDs) in the FLT3 gene was negative.

RAD21 encodes a subunit of the cohesin complex, which controls the separation of sister chromatids during mitosis and functions in other processes including transcription and DNA repair. Mutations associated with myeloid malignancies are found throughout the gene and cause inactivation of the protein (16). About 3% of AML and 1–2% of MDS cases are found to have mutations in the RAD21 gene (17, 18). A higher frequency of cohesin defects has been observed in secondary AML and high-risk MDS patients, and cohesin defects have been associated with poor overall survival in MDS patients (16).

Outcome

The patient underwent induction with conventional idarubicin and cytarabine. This was complicated only by neutropenic fever without an identified infectious source. A complete cytogenetic remission (CR) was achieved. Molecular profiling was not repeated at the time of her remission bone marrow biopsy. She proceeded immediately to four cycles of consolidation with

high-dose cytarabine, which were completed without delays or major complications. She has remained in CR for 18 months.

**Patient #2
Clinicopathologic Findings**

A 63-year-old female with a history significantly only for a renal mass treated with partial nephrectomy was transferred to our hospital with fatigue, bone pain, and an abnormal CBC. She was found to have a WBC count of $6.1 \times 10^3/\mu\text{L}$ with 67% blasts, hemoglobin of 9.1 g/dL, and platelets $4 \times 10^3/\mu\text{L}$. Bone marrow biopsy showed an increase in number of blasts (75% by manual count). The blasts were medium in size, had fine nuclear chromatin, small nucleoli, and scant cytoplasm. No cytoplasmic granules or Auer rods were seen. Bone marrow flow cytometry detected myeloblasts (69%) with the following antigenic pattern: CD4+ (dim, partial), CD13- (partial, dim), CD14-, CD33+, CD34+, CD38+ (partial, dim), CD56-, CD61-, CD64-, CD117+, and HLA-DR+ (dim) (Table 1). A diagnosis of AML was made.


Conventional Cytogenetics and FISH

Similar to Patient #1, conventional cytogenetics revealed an apparently reciprocal translocation between the long arms

of chromosomes 8 and 21 at 8q22 and 21q22 [t(8;21)] in twenty of twenty metaphases analyzed. However, FISH on interphase nuclei showed two atypical signal patterns for the RUNX1/RUNX1T1 translocation probe set: the first was consistent with the presence of a derivative chromosome (one fusion signal) presumably arising from a reciprocal t(8;21) translocation along with one copy of RUNX1T1 (1R) and two copies of RUNX1 (2G), and the second showed two copies of RUNX1T1 (2R) and three copies of RUNX1 (3G). While metaphase FISH analysis later proved that the

derivative chromosome represented a der(8), whether the extra RUNX1 signal resulted from a trisomy 21 or from sequential structural alterations following a t(8;21) was unable to be determined. In addition, a low level TP53 deletion was observed (Figure 2). The final cytogenetic diagnosis for this patient was:

46,XX,der(8)t(8;21)(q22;q22),der(21)t(8;21)del(8)(q22q22)(20).
nuc ish(RUNX1T1x2,RUNX1x3)(RUNX1 conRUNX1T1x1)[92/200]/(RUNX1T1x2,RUNX1x3)[92/200], (TP53x1,CEP17x2)[37/200], (ASS1,ABL1,PML,CBFB,RARA,BCR)x2[200].



Molecular Pathology Assays

Pathogenic mutations were found in three genes: ASXL1, DNMT3A, and IDH1 (Table 2). The studies of JAK2 V617F mutation and internal tandem duplications (ITDs) in the FLT3 gene were both negative.

ASXL1 encodes a chromatin-binding Polycomb group (PcG) protein involved in transcriptional regulation (19). Somatic mutations in ASXL1 have been reported in 10.8% adults with *de novo* AML, and in 17.2% of AML cases with intermediate risk cytogenetics (20, 21). DNMT3A encodes DNA (cytosine-5)-methyltransferase 3A and is essential for establishing genome-wide patterns of CpG methylation during development. It is also important for regulating gene expression, parental imprinting, and maintaining genome integrity (22). The Cancer Genome Atlas Research Network identified mutations in the DNMT3A gene in 51/200 (26%) *de novo* AML samples (17). Isocitrate dehydrogenases, which include IDH1 and IDH2, catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate (alpha-ketoglutarate) (23, 24). Approximately 6–9% of AML cases are found to have mutations in the IDH1 gene, with a higher frequency in normal karyotype-AML (8–16%) (19). Studies of the prognostic significance of ASXL1, DNMT3A, and IDH mutations in AML have reported complex and sometimes conflicting results, although most reports support negative effects on prognosis (19–21). The co-occurrence of mutations in epigenetic regulators, including ASXL1, DNMT3A, and IDH1, has also been reported (25–27). However, the frequency and clinical consequences of this combination of mutations in core binding factor AML are not well-characterized.

Outcome

The patient underwent treatment with conventional idarubicin and cytarabine induction. This was complicated by neutropenic fever without an identified infectious source and the development of a rash that was thought to be due to cytarabine. A cytogenetic CR was achieved. Molecular profiling was not repeated at the time of her remission bone marrow biopsy. She proceeded immediately to consolidation with high dose cytarabine. Unfortunately, she completed 3 cycles and then her disease relapsed. Cytogenetics at the time of relapse showed the same t(8;21), and molecular profiling identified the same mutations in ASXL1, DNMT3A, and IDH1 that were present at diagnosis. She underwent re-induction on a clinical trial, however, her disease was refractory. She subsequently began treatment with an IDH1 inhibitor and her disease was stable for ~4 months. At the time of disease progression, she opted for hospice. The patient died 14 months after her diagnosis.

DISCUSSION

Although AML with t(8;21)(q22;q22) is generally associated with a favorable prognosis, it is unclear if the same can be said for variant t(8;21) (1–3, 11). Our patients had similar variant subtypes of t(8;21) and were treated with idarubicin and cytarabine induction therapy. Both achieved a complete remission, however, Patient #1 has remained in CR after

consolidation chemotherapy, while Patient #2 relapsed and subsequently died.

Published outcomes for other variant cases are similarly heterogeneous. Kawakami et al. (13) described a case of a 37-year-old man with a variant t(8;21) that demonstrated a three way translocation between chromosomes 8, 9, and 21. This patient had an AML1/ETO fusion transcript that was identical to the fusion transcript found in patients with classic t(8;21), however, he did not achieve a complete remission with idarubicin and cytarabine (13). Similarly, a 15-year-old patient with a four way translocation t(8;17;15;21)(q22;q23;q15;q22) was reported, and he also showed rapid progression of his disease (28). An additional variant form of t(8;21) was reported in a 10-year-old female with a translocation between chromosomes 4, 8, and 21, with loss of the X chromosome and a gain of chromosome 6. She had an early relapse and a poor outcome (29).

Another paper reported three cases of variant t(8;21) AML. Two patients had three way translocations; the first with a translocation between chromosomes 8, 18, and 21 as well as a del(7)(q32q34) and the second with a translocation involving chromosomes 2, 8, and 21 with loss of the Y chromosome. The third patient had a derivative eight with the interstitial inverted insertion of 21q and concurrent monosomy 21; this patient achieved CR for 15 months before relapse (11). Another author presented four patients with variant forms of t(8;21). Two of these patients had three-way translocations, one with t(1;8;21) and the other with t(8;11;21), and a third patient had a four way translocation between chromosomes 4, 8, 12, and 21. The fourth patient reported had three neoplastic clones in which the segment of chromosome 8 containing bands q22 through q24.1 had been duplicated and inverted (the t(8;21) had been inserted within the duplicated segment. All four of these patients achieved a CR (30). Another patient described in the literature with a complex translocation involving chromosomes 1, 8, and 21 with del 9q22 and loss of the X chromosome had no reported outcome (31).

Although the prognosis for patients with variant t(8;21) is generally unclear, certain markers have been associated with outcomes. For example, loss of the sex chromosome and del (9q) have been associated with shorter overall survival, and trisomy 4 has been thought to be associated with a poorer prognosis (11, 13). AML1/ETO frequently expresses positivity for CD19 and CD56 and, although CD19 positivity is not thought to alter prognosis, it has been reported that CD56 is associated with shorter remission time and survival. Additionally, c-kit and EML are thought to be associated with a negative outcome (13).

The cytogenetic abnormalities that occur from t(8;21)(q22;q22) result in the disruption of a transcription factor that functions as a regulator of hematopoiesis. In patients with classical t(8;21) AML, remission rates after induction chemotherapy with an anthracycline and cytarabine approaches 90% (10). Although these responses are considered favorable, the median survival for these patients, according to long term follow up reports, is 5 years or less (2). Variant t(8;21) is much less common than traditional CBF AML, and it has been reported that the majority of patients with variant rearrangements have a complex translocation involving a third chromosome (28). The reported responses to therapy for these patients are varied.

Little is known about the molecular landscape of patients with variant t(8;21). Previously reported cases did not include molecular data, likely because many were published prior to the routine use of NGS in AML diagnosis. However, extrapolation from the body of literature regarding molecular mutations in classical t(8;21) AML may be possible. In general, tyrosine kinase mutations such as KIT and FLT3 are most common in this subset of patients and co-mutations in these genes can be seen (32–34). Mutations in KIT have been clearly shown to correlate with shortened remission duration and decreased overall survival in t(8;21) AML (35, 36). The prognostic significance of KIT mutations in inv(16) AML is less clearly defined (37, 38). Mutations in epigenetic regulators and members of the cohesin complex, including ASXL1, IDH1/2, and RAD21, have also been identified in a significant subset of t(8;21) AML. Interestingly, these mutations are vanishingly rare in inv(16) AML (32). Whether the genetic profile of variant t(8;21) is similar to that of classical t(8;21) remains to be determined, however, the patients presented here do share similar molecular signatures to those described in CBF AML.

We provide the first description of two cases of variant t(8;21) along with their molecular profiles. Additional reports of similar cases are needed in order to better determine the

interplay between, and the clinical significance of, the cytogenetic and molecular abnormalities. The two patients presented in this paper with variant t(8;21) both achieved complete remission with standard induction therapy, however, only one had a durable response.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

LW, JC, Z-XW, and JL provided substantial contribution to the conception, drafting, editing, and final approval of this manuscript.

REFERENCES

- Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with *de novo* acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). *Blood*. (2002) 100:4325–36. doi: 10.1182/blood-2002-03-0772
- Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. *Clin Lymphoma Myeloma Leuk*. (2013) 13:153–8. doi: 10.1016/j.clml.2012.11.006
- Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn J-Y, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the french CBF-AML intergroup. *J Clin Oncol*. (2009) 27:4747–53. doi: 10.1200/JCO.2008.21.0674
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. *Blood*. (1998) 92:2322–33.
- Fu L, Shi J, Liu A, Zhou L, Jiang M, Fu H, et al. A microcircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. *Int J Cancer*. (2017) 140:653–61. doi: 10.1002/ijc.30481
- Lam K, Zhang D-E. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. *Front Biosci*. (2012) 17:1120–39. doi: 10.2741/3977
- Stuardo M, Nicovani S, Javed A, Gutierrez S. Breakpoint regions of ETO gene involved in (8; 21) leukemic translocations are enriched in acetylated histone H3. *J Cell Biochem*. (2013) 114:2569–76. doi: 10.1002/jcb.24605
- Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. *Gene*. (2003) 303:1–10. doi: 10.1016/S0378-1119(02)01172-1
- Asou N. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. *Crit Rev Oncol Hematol*. (2003) 45:129–50. doi: 10.1016/S1040-8428(02)00003-3
- Paschka P. Core binding factor acute myeloid leukemia. *Semin Oncol*. (2008) 35:410–7. doi: 10.1053/j.seminoncol.2008.04.011
- Bae SY, Kim JS, Ryeu BJ, Lee KN, Lee CK, Kim YK, et al. Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases. *Cancer Genet Cytogenet*. (2010) 199:31–7. doi: 10.1016/j.cancergencyto.2009.10.002
- Kim H, Moon HW, Hur M, Yun YM, Lee MH. Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature. *Acta Haematol*. (2011) 125:237–41. doi: 10.1159/000323425
- Kawakami K, Nishii K, Hyou R, Watanabe Y, Nakao M, Mitani H, et al. A case of acute myeloblastic leukemia with a novel variant of t(8;21)(q22;q22). *Int J Hematol*. (2008) 87:78–82. doi: 10.1007/s12185-007-0010-2
- Lin S, Mulloy JC, Goyama S. RUNX1-ETO leukemia. In: Groner Y, Ito Y, Liu P, Neil JC, Speck NA, van Wijnen A, editors. *RUNX Proteins in Development and Cancer*. Singapore: Springer Singapore (2017). p. 151–73. doi: 10.1007/978-981-10-3233-2_11
- Erickson P, Gao J, Chang K, Look T, Whisenant E, Raimondi S, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. *Blood*. (1992) 80:1825–31.
- Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. *Blood*. (2014) 124:1790–8. doi: 10.1182/blood-2014-04-567057
- Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult *de novo* acute myeloid leukemia. *N Engl J Med*. (2013) 368:2059–74. doi: 10.1056/NEJMoa1301689
- Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia*. (2013) 28:241. doi: 10.1038/leu.2013.336
- Abdel-Wahab O, Adli M, LaFave Lindsay M, Gao J, Hricik T, Shih Alan H, et al. ASXL1 Mutations promote myeloid transformation through loss of PRC2-mediated gene repression. *Cancer Cell*. (2012) 22:180–93. doi: 10.1016/j.ccr.2012.06.032
- Chou W-C, Huang H-H, Hou H-A, Chen C-Y, Tang J-L, Yao M, et al. Distinct clinical and biological features of *de novo* acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. *Blood*. (2010) 116:4086–94. doi: 10.1182/blood-2010-05-283291
- Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate

- risk karyotype and are independently associated with an adverse outcome. *Leukemia*. (2012) 27:82. doi: 10.1038/leu.2012.262
22. Roller A, Grossmann V, Bacher U, Poetzing F, Weissmann S, Nadarajah N, et al. Landmark analysis of DNMT3A mutations in hematological malignancies. *Leukemia*. (2013) 27:1573. doi: 10.1038/leu.2013.65
 23. Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttill J, Zhang L, Khrebtkova I, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic Landscapes in acute myeloid leukemia. *PLoS Genet*. (2012) 8:e1002781. doi: 10.1371/journal.pgen.1002781
 24. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. *Cancer Cell*. (2011) 19:17–30. doi: 10.1016/j.ccr.2010.12.014
 25. Kao H-W, Liang D-C, Wu J-H, Kuo M-C, Wang P-N, Yang C-P, et al. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. *Neoplasia*. (2014) 16:481–8. doi: 10.1016/j.neo.2014.06.002
 26. Wang M, Yang C, Zhang L, Schaar DG. Molecular mutations and their cooccurrences in cytogenetically normal acute myeloid leukemia. *Stem Cells Int*. (2017) 2017:11. doi: 10.1155/2017/6962379
 27. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. (2016) 374:2209–21. doi: 10.1056/NEJMoa1516192
 28. Vieira LS, Oliveira V, Ambrósio AP, Marques B, Pereira AM, Hagemeyer A, et al. Translocation (8;17;15;21)(q22;q23;q15;q22) in acute myeloid leukemia (M2): a four-way variant of t(8;21). *Cancer Genet Cytogenet*. (2001) 128:104–7. doi: 10.1016/S0165-4608(01)00404-6
 29. Kelly MJ, Meloni-Ehrig AM, Manley PE, Altura RA. Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6. *Cancer Genet Cytogenet*. (2009) 189:48–52. doi: 10.1016/j.cancergencyto.2008.09.011
 30. Valbuena JR, Medeiros LJ, Huang L, Lin P, Abruzzo LV. Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature. *Am J Clin Pathol*. (2006) 125:267–72. doi: 10.1309/8VJ4-V9PG-3TRJ-TLVH
 31. Ahmad F, Kokate P, Chheda P, Dalvi R, Das BR, Mandava S. Molecular cytogenetic findings in a three-way novel variant of t(1;8;21)(p35;q22;q22): a unique relocation of the AML1/ETO fusion gene 1p35 in AML-M2. *Cancer Genet Cytogenet*. (2008) 180:153–7. doi: 10.1016/j.cancergencyto.2007.10.005
 32. Duployez N, Marceau-Renaut A, Boissel N, Petit A, Buccini M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. *Blood*. (2016) 127:2451–9. doi: 10.1182/blood-2015-12-688705
 33. Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. *Hematol Oncol Stem Cell Ther*. (2017) 10:1–7. doi: 10.1016/j.hemonc.2016.08.005
 34. Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, et al. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. *Blood*. (2018) 132:187–96. doi: 10.1182/blood-2018-03-837781
 35. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. *Blood*. (2006) 107:3463–8. doi: 10.1182/blood-2005-09-3640
 36. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). *Leukemia*. (2006) 20:965–70. doi: 10.1038/sj.leu.2404188
 37. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. *J Clin Oncol*. (2006) 24:3904–11. doi: 10.1200/JCO.2006.06.9500
 38. Chen W, Xie H, Wang H, Chen L, Sun Y, Chen Z, et al. Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. *PLoS ONE*. (2016) 11:e0146614. doi: 10.1371/journal.pone.0146614

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a shared affiliation, though no other collaboration, with one of the author LW.

Copyright © 2019 Wilde, Cooper, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.